BR0114642A - Prevenção de doenças através da reativação do timo - Google Patents
Prevenção de doenças através da reativação do timoInfo
- Publication number
- BR0114642A BR0114642A BR0114642-4A BR0114642A BR0114642A BR 0114642 A BR0114642 A BR 0114642A BR 0114642 A BR0114642 A BR 0114642A BR 0114642 A BR0114642 A BR 0114642A
- Authority
- BR
- Brazil
- Prior art keywords
- cells
- thymus
- patient
- lhrh
- gene
- Prior art date
Links
- 210000001541 thymus gland Anatomy 0.000 title abstract 5
- 230000007420 reactivation Effects 0.000 title abstract 3
- 230000006806 disease prevention Effects 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 abstract 7
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 abstract 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 abstract 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 abstract 1
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 abstract 1
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 abstract 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 abstract 1
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000000735 allogeneic effect Effects 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 abstract 1
- 210000003738 lymphoid progenitor cell Anatomy 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000003643 myeloid progenitor cell Anatomy 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 230000001568 sexual effect Effects 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
- 208000010648 susceptibility to HIV infection Diseases 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2046—IL-7
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Reproductive Health (AREA)
- Genetics & Genomics (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
Abstract
"PREVENçãO DE DOENçAS ATRAVéS DA REATIVAçãO DO TIMO". A presente descrição refere-se aos processos para terapia gênica utilizando células tronco hematopoiéticas, células progenitoras linfóides e/ou células progenitoras mielóides. As células são modificadas geneticamente para fornecerem um gene que é expresso nestas células e em sua progênie após a diferenciação. Em uma modalidade preferida as células contêm um gene ou um fragmento de gene que confere às células resistência à infecção e/ou replicação do HIV. As células são administradas a um paciente em associação com o tratamento para reativar o timo do paciente. As células podem ser autólogas, singenéicas, alogenéicas ou xenogenéicas, uma vez que é criada uma tolerância às células estranhas no paciente durante a reativação do timo. Em uma modalidade preferida as células tronco hematopoiéticas são CD34+. O timo do paciente é reativado através da interrupção da sinalização mediada por esteróide sexual para o timo. Em uma modalidade preferida, esta interrupção é criada através da administração de agonistas para LHRH, antagonistas para LHRH, anticorpos anti-receptor para LHRH, vacinas anti-LHRH ou combinações dos mesmos.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79530200A | 2000-10-13 | 2000-10-13 | |
US79528600A | 2000-10-13 | 2000-10-13 | |
AUPR0745A AUPR074500A0 (en) | 2000-10-13 | 2000-10-13 | Treatment of t cell disorders |
US75598301A | 2001-01-05 | 2001-01-05 | |
US75564601A | 2001-01-05 | 2001-01-05 | |
US09/755,965 US20010046486A1 (en) | 2000-04-17 | 2001-01-05 | Stimulation of thymus for vaccination development |
US75891001A | 2001-01-10 | 2001-01-10 | |
US09/965,395 US20020081276A1 (en) | 1999-04-15 | 2001-09-26 | Disease prevention by reactivation of the thymus |
PCT/IB2001/002745 WO2002030259A2 (en) | 2000-10-13 | 2001-10-12 | Disease prevention by reactivation of the thymus |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0114642A true BR0114642A (pt) | 2004-01-20 |
Family
ID=27570138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0114642-4A BR0114642A (pt) | 2000-10-13 | 2001-10-12 | Prevenção de doenças através da reativação do timo |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1363703A4 (pt) |
CN (1) | CN100406025C (pt) |
AP (1) | AP2003002796A0 (pt) |
AU (1) | AU1632302A (pt) |
BR (1) | BR0114642A (pt) |
CA (1) | CA2462681A1 (pt) |
IL (1) | IL155414A0 (pt) |
NZ (1) | NZ525830A (pt) |
WO (1) | WO2002030259A2 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004103271A2 (en) * | 2003-04-18 | 2004-12-02 | Norwood Immunology, Ltd. | Disease prevention and vaccination prior to thymic reactivations |
CA2699087A1 (en) * | 2007-09-11 | 2009-04-16 | Dorian Bevec | Use of a peptide as a therapeutic agent |
AU2010282280B2 (en) | 2009-08-14 | 2016-06-09 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of IL-15 to increase thymic output and to treat lymphopenia |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
CN104383541A (zh) | 2011-10-21 | 2015-03-04 | 艾伯维公司 | 用于治疗hcv的包含至少两种直接抗病毒剂和利巴韦林但无干扰素的方法 |
DK2583680T1 (da) | 2011-10-21 | 2015-01-19 | Abbvie Inc | Mono (PSI-7977) eller kombinationsbehandling af DAA til anvendelse ved behandling af HCV |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
CA3022119A1 (en) | 2016-04-28 | 2017-11-02 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4049805A (en) * | 1975-09-30 | 1977-09-20 | Akzona Incorporated | Steroidal erythropoietic agents and therapeutic compositions and methods |
CN1058500C (zh) * | 1993-02-03 | 2000-11-15 | 施塞克龙药品公司 | 胸腺素α-1衍生物 |
CA2161797A1 (en) * | 1993-05-17 | 1994-11-24 | Megan Sykes | Xenograft thymus |
AUPP971499A0 (en) * | 1999-04-12 | 1999-05-06 | Opentec Pty. Limited | On-line electoral system |
AUPP977899A0 (en) * | 1999-04-15 | 1999-05-13 | Monash University | Improvement of t cell mediated immunity |
-
2001
- 2001-10-12 WO PCT/IB2001/002745 patent/WO2002030259A2/en active IP Right Grant
- 2001-10-12 IL IL15541401A patent/IL155414A0/xx unknown
- 2001-10-12 BR BR0114642-4A patent/BR0114642A/pt not_active IP Right Cessation
- 2001-10-12 EP EP01986582A patent/EP1363703A4/en not_active Ceased
- 2001-10-12 NZ NZ525830A patent/NZ525830A/en unknown
- 2001-10-12 AU AU1632302A patent/AU1632302A/xx active Pending
- 2001-10-12 CA CA002462681A patent/CA2462681A1/en not_active Abandoned
- 2001-10-12 AP APAP/P/2003/002796A patent/AP2003002796A0/en unknown
- 2001-10-12 CN CNB018201342A patent/CN100406025C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
IL155414A0 (en) | 2003-11-23 |
CA2462681A1 (en) | 2002-04-18 |
NZ525830A (en) | 2005-07-29 |
WO2002030259A9 (en) | 2003-08-07 |
WO2002030259A3 (en) | 2002-07-04 |
AU1632302A (en) | 2002-04-22 |
EP1363703A4 (en) | 2006-06-07 |
EP1363703A2 (en) | 2003-11-26 |
CN100406025C (zh) | 2008-07-30 |
AP2003002796A0 (en) | 2003-06-30 |
WO2002030259A2 (en) | 2002-04-18 |
CN1505537A (zh) | 2004-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2020201856A1 (en) | Methods modulating immunoregulatory effect of stem cells | |
Bonsack et al. | Mesenchymal stem cell therapy alleviates the neuroinflammation associated with acquired brain injury | |
JP5294635B2 (ja) | コポリマー1と組み合わせた、神経発生の誘発及び幹細胞治療 | |
US11872250B2 (en) | Methods for inducing an immune response by administering activated mesenchymal stem cells | |
Colpo et al. | Mesenchymal stem cells for the treatment of neurodegenerative and psychiatric disorders | |
BR0114642A (pt) | Prevenção de doenças através da reativação do timo | |
AU2005220156A1 (en) | Peptides of IL1 beta and TNF alpha and method of treatment using same | |
US20020142462A1 (en) | Methods for mobilizing hematopoietic facilitating cells and hematopoietic stem cells into the peripheral blood | |
Yang et al. | The role of interleukin-12 in preserving the graft-versus-leukemia effect of allogeneic CD8 T cells independently of GVHD | |
Dudakov et al. | Greater than the sum of their parts: combination strategies for immune regeneration following allogeneic hematopoietic stem cell transplantation | |
BR0114639A (pt) | Terapia genética de célula tronco hematopoiética | |
Koreth et al. | Low-dose interleukin-2 in the treatment of autoimmune disease | |
JP2005516983A (ja) | チルホスチン化合物を用いた骨髄機能非除去的な寛容原性処置 | |
KR20190122717A (ko) | 면역 증강제, 면역치료 약학적 조성물 및 이의 제조 및 용도 | |
BR0114641A (pt) | Estimulação do timo para o desenvolvimento de vacina | |
Pfeiffer | ITP: AMG 531 Shows Good Activity in Boosting Platelet Production | |
WO2002030257A3 (en) | Normalization of defective t cell responsiveness through manipulation of thymic regeneration | |
Conti et al. | Therapeutic response in subtypes of major depression. | |
Carlson | Steroid-Resistant GvHD Responds to Novel Treatments | |
Carlson | Mesenchymal stem cells modulate immune system in GvHD patients | |
Pittenger et al. | Immunological properties of mesenchymal stem cells isolated from bone marrow and umbilical cord |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: NORWOOD IMMUNOLOGY LTD. (AU) Free format text: TRANSFERIDO DE: MONASH UNIVERSITY |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDA DES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2060 DE 29/06/2010. |
|
B15K | Others concerning applications: alteration of classification |
Ipc: A61K 35/28 (2006.01), A61P 31/00 (2006.01), A61P 3 |